Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
April 15, 2008
Novartis initiated, positive in randomized phase II trial- I think they (we) may have something!
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: GLG Expert Contributor
"ASA404 is a Tumor-Vascular Disrupting Agent (Tumor-VDA) that selectively causes the collapse of existing tumor blood supply leading to extensive tumor cell death." It is being combined with Taxol and carboplatin in a randomized phase III study.
April 15, 2008
Alimta (Lilly): Approved as First Line Agent in Europe for Non Squamous Cell Lung Ca!!!
Analysis of: ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Alimta will be used first line with Cis Platin as a primary therapy for non squamous non small cell lung cancer (NSCLCA)
April 14, 2008
Physician owned hospitals. Beneficial to whom? Certainly not the patient!!!
Analysis of: U.S. Reps give boost to physician-owned hospitals | www.fiercehealthcare.com
Author: GLG Expert Contributor
2 Texas U.S. Reps think that physcian owned hospitals are OK?
April 14, 2008
Co-Payments for Expensive Drugs Soar: Does Pharma really want governmental controls?
Analysis of: Co-Payments for Expensive Drugs Soar | www.nytimes.com
Author: GLG Expert Contributor
Co payments which had been $5/10/20 in the past are now a %age of the cost. When the cost may be upwards of $50-100K and you have a 20% co pay you can see the costs that are transfered back to the insured.
April 11, 2008
Genentech/Avastin: Drp in sales?? Be patient!
Analysis of: Genentech Profit Jumps By 12% on Solid Revenue | online.wsj.com
Author: GLG Expert Contributor
Has Avastin "hit the wall" as far as increased sales are concerned? Growth in the breast cancer market has not been as exuberant as expected.
April 10, 2008
Millennium purchase may open up avenues for more sales??
Analysis of: Takeda to Buy Millennium In $8.8 Billion Deal | online.wsj.com
Author: GLG Expert Contributor
Japan's biggest (by revenue) drug manufacturer has placed a bid For Millennium and it's primary product Velcade.
April 10, 2008
Sickle Cell Anemia: Does Icagen, Inc have an answer in senicapoc (ICA-17043)?
Analysis of: Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
"Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC) hydration." This appears to decrease hemolysis and increase hemoglobin levels.
April 9, 2008
Bexarotene (Ligand) It's SPIRIT is alive in a subset of lung cancer patients.
Analysis of: Phase III Trial Comparing Carboplatin, Paclitaxel, and Bexarotene With Carboplatin and Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: SPIRIT II | jco.ascopubs.org
Author: GLG Expert Contributor
This study, as well as a companion paper in the same JCO (Spirit I & II) http://jco.ascopubs.org/cgi/content/full/26/11/1886 Show that the subset of patients with markedly increase in lipids, survived > 12 mo!!
April 9, 2008
Oncophage(R) : Let's wait until the results are duplicated in Costa Rica.......
Analysis of: Oncophage(R) Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Antigenics Inc. (NASDAQ: AGEN) had to go to Russia to perform this clinical trial???
April 4, 2008
Genetic drivers of lung cancer risk identified.
Analysis of: Studies Find Genetic Link to Smoking | www.nytimes.com
Author: GLG Expert Contributor
Gene driven nicotine receptors will predispose to increased smoking. What will this lead to?? Increased addiction due to mutations increases cancer risk.

Previous Page : 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next111 to 120 of 450

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440